Related Experiment Video
Updated: Aug 9, 2026

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
Low-dose i.v. acetylcholine acts as a "preconditioning-mimetic" in the canine model
1Heart Institute, Hospital of the Good Samaritan, Los Angeles, CA 90017-2395, USA.
Abstract:
Brief episodes of ischemia paradoxically protect or "precondition" the heart and reduce infarct size caused by a subsequent, more sustained, coronary artery occlusion, perhaps by stimulation of adenosine receptors coupled to muscarinic receptors via the inhibitory G protein. However, brief ischemia is not a desirable form of therapy. Using the anesthetized canine model, we therefore sought to determine if small intravenous (i.v.) doses of the muscarinic agonist acetylcholine would provide a therapeutically feasible means to mimic preconditioning. Four groups of dogs underwent a 40-minute intervention period, followed by 1 hour of coronary occlusion and 5 hours of reperfusion: 8 received two i.v. doses of acetylcholine (0.01 mg each) at 40 minutes and 5 minutes before the sustained occlusion; 8 received equipotent doses of nitroglycerin (0.05 mg; a vasodilator that does not act via the M2 muscarinic receptor); 7 received conventional ischemic preconditioning (four 5-minute episodes of coronary occlusion, each interrupted by 5 minutes of reperfusion); and 8 controls received no intervention. Coronary blood flow and hemodynamic parameters were monitored throughout the protocol, regional myocardial blood flow was measured during the sustained occlusion by injection of radiolabeled microspheres, and infarct size was assessed by tetrazolium staining. All four groups were equally ischemic during coronary occlusion. However, infarct size was reduced significantly in both the preconditioned and acetylcholine-treated dogs when compared with controls (6% +/- 2% [p < 0.01 vs controls], 10% +/- 2% [p < 0.05 vs controls], and 19% +/- 3% of the myocardium at risk).(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Depolarizing Blockers: Pharmocokinetics

